155 related articles for article (PubMed ID: 3086569)
21. Rabies vaccination: comparison of neutralizing antibody responses after priming and boosting with different combinations of DNA, inactivated virus, or recombinant vaccinia virus vaccines.
Lodmell DL; Ewalt LC
Vaccine; 2000 May; 18(22):2394-8. PubMed ID: 10738096
[TBL] [Abstract][Full Text] [Related]
22. Protective efficacy in mice of post-exposure vaccination with vaccinia virus recombinant expressing either rabies virus glycoprotein or nucleoprotein.
Fujii H; Takita-Sonoda Y; Mifune K; Hirai K; Nishizono A; Mannen K
J Gen Virol; 1994 Jun; 75 ( Pt 6)():1339-44. PubMed ID: 8207400
[TBL] [Abstract][Full Text] [Related]
23. Immunity against the European bat rabies (Duvenhage) virus induced by rabies vaccines: an experimental study in mice.
Lafon M; Bourhy H; Sureau P
Vaccine; 1988 Aug; 6(4):362-8. PubMed ID: 2461007
[TBL] [Abstract][Full Text] [Related]
24. Canine rabies DNA vaccination: a single-dose intradermal injection into ear pinnae elicits elevated and persistent levels of neutralizing antibody.
Lodmell DL; Parnell MJ; Weyhrich JT; Ewalt LC
Vaccine; 2003 Sep; 21(25-26):3998-4002. PubMed ID: 12922136
[TBL] [Abstract][Full Text] [Related]
25. Polygenic control of antibody production and correlation with vaccine induced resistance to rabies virus in high and low antibody responder mice.
De Franco M; Massa S; Vassão RC; Siqueira M; Sant'Anna OA
Arch Virol; 1996; 141(8):1397-406. PubMed ID: 8856022
[TBL] [Abstract][Full Text] [Related]
26. Post-exposure DNA vaccination protects mice against rabies virus.
Lodmell DL; Ewalt LC
Vaccine; 2001 Mar; 19(17-19):2468-73. PubMed ID: 11257379
[TBL] [Abstract][Full Text] [Related]
27. Exhaustive Exercise Does Not Affect Humoral Immunity and Protection after Rabies Vaccination in a Mouse Model.
Xia L; Li M; Zhang Y; Ruan J; Pei J; Shi J; Fu ZF; Zhao L; Zhou M; Tian D
Virol Sin; 2018 Jun; 33(3):241-248. PubMed ID: 29594957
[TBL] [Abstract][Full Text] [Related]
28. Antigenic variation in rabies and rabies-related viruses: cross-protection independent of glycoprotein-mediated virus-neutralizing antibody.
Dietzschold B; Tollis M; Rupprecht CE; Celis E; Koprowski H
J Infect Dis; 1987 Nov; 156(5):815-22. PubMed ID: 3655404
[TBL] [Abstract][Full Text] [Related]
29. Induction of protective immunity against rabies by immunization with rabies virus ribonucleoprotein.
Dietzschold B; Wang HH; Rupprecht CE; Celis E; Tollis M; Ertl H; Heber-Katz E; Koprowski H
Proc Natl Acad Sci U S A; 1987 Dec; 84(24):9165-9. PubMed ID: 3480536
[TBL] [Abstract][Full Text] [Related]
30. Evaluation of an inactivated rabies virus vaccine in domestic ferrets.
Rupprecht CE; Gilbert J; Pitts R; Marshall KR; Koprowski H
J Am Vet Med Assoc; 1990 May; 196(10):1614-6. PubMed ID: 2347753
[TBL] [Abstract][Full Text] [Related]
31. Adult dogs receiving a rabies booster dose with a recombinant adenovirus expressing rabies virus glycoprotein develop high titers of neutralizing antibodies.
Tims T; Briggs DJ; Davis RD; Moore SM; Xiang Z; Ertl HC; Fu ZF
Vaccine; 2000 Jun; 18(25):2804-7. PubMed ID: 10812222
[TBL] [Abstract][Full Text] [Related]
32. Induction of protective immunity by topic application of a recombinant adenovirus expressing rabies virus glycoprotein.
Lees CY; Briggs DJ; Wu X; Davis RD; Moore SM; Gordon C; Xiang Z; Ertl HC; Tang DC; Fu ZF
Vet Microbiol; 2002 Apr; 85(4):295-303. PubMed ID: 11856579
[TBL] [Abstract][Full Text] [Related]
33. Studies on clinical trials and immune effect of a new purified rabies vaccine prepared from Vero cells.
Dong G; Zheng H; Liu Z
Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi; 2000 Mar; 14(1):19-23. PubMed ID: 11503018
[TBL] [Abstract][Full Text] [Related]
34. Rabies antibody titers in vaccinees: protection, failure and prospects.
Dutta JK; Pradhan SC; Dutta TK
Int J Clin Pharmacol Ther Toxicol; 1992 Mar; 30(3):107-12. PubMed ID: 1506120
[TBL] [Abstract][Full Text] [Related]
35. Genetics of natural resistance to herpes simplex virus type 1 latent infection of the peripheral nervous system in mice.
Kastrukoff LF; Lau AS; Puterman ML
J Gen Virol; 1986 Apr; 67 ( Pt 4)():613-21. PubMed ID: 3007658
[TBL] [Abstract][Full Text] [Related]
36. Mechanisms of protective immunity against S. mansoni infection in mice vaccinated with irradiated cercariae. VI. Influence of the major histocompatibility complex.
Sher A; Hieny S; James S
Parasite Immunol; 1984 Jul; 6(4):319-28. PubMed ID: 6472878
[TBL] [Abstract][Full Text] [Related]
37. Virus neutralizing antibody response in mice and dogs with a bicistronic DNA vaccine encoding rabies virus glycoprotein and canine parvovirus VP2.
Patial S; Chaturvedi VK; Rai A; Saini M; Chandra R; Saini Y; Gupta PK
Vaccine; 2007 May; 25(20):4020-8. PubMed ID: 17391817
[TBL] [Abstract][Full Text] [Related]
38. Susceptibility to a mouse acquired immunodeficiency syndrome is influenced by the H-2.
Hamelin-Bourassa D; Skamene E; Gervais F
Immunogenetics; 1989; 30(4):266-72. PubMed ID: 2551819
[TBL] [Abstract][Full Text] [Related]
39. The importance of MHC-I and MHC-II responses in vaccine efficacy against lethal herpes simplex virus type 1 challenge.
Ghiasi H; Roopenian DC; Slanina S; Cai S; Nesburn AB; Wechsler SL
Immunology; 1997 Jul; 91(3):430-5. PubMed ID: 9301533
[TBL] [Abstract][Full Text] [Related]
40. Antigenic variants of rabies virus.
Wiktor TJ; Koprowski H
J Exp Med; 1980 Jul; 152(1):99-112. PubMed ID: 6156982
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
